3DMatrix
Commercial- Indications
- Surgical applications
Company intelligence / Profile preview
PrintBio
Miami, Florida, United Statesprintbio.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
PrintBio has received FDA clearance for 3DMatrix™, the first 3D-printed resorbable surgical mesh. They are also conducting a Phase 1/2a clinical trial for AuriNovo™, a 3D-bioprinted ear implant for patients with microtia[4].
- Therapeutic areas
- OtherOncologyRare DiseasesNeurology
- Modalities
- 3D-bioprinted living tissue implantsresorbable surgical mesh
- Industry
- Implantable Medical Devices
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on PrintBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PrintBio.